Thrombospondin-1 Type 1 Repeats in a Model of Inflammatory Bowel Disease: Transcript Profile and Therapeutic Effects

Zenaida P. Lopez-Dee1*, Srirad V. Chittur2, Bhumi Patel1, Rebecca Stanton1, Michelle Wakeley1, Brittany Lippert1, Anastasya Menaker1, Bethany Eiche1, Robert Terry1, Linda S. Gutierrez1*

1 Department of Biology, Wilkes University, Wilkes-Barre, Pennsylvania, United States of America, 2 Center for Functional Genomics, University at Albany, State University of New York, Rensselaer, New York, United States of America

Abstract

Thrombospondin-1 (TSP-1) is a matricellular protein with regulatory functions in inflammation and cancer. The type 1 repeats (TSR) domains of TSP-1 have been shown to interact with a wide range of proteins that result in the anti-angiogenic and anti-tumor properties of TSP-1. To ascertain possible functions and evaluate potential therapeutic effects of TSRs in inflammatory bowel disease, we conducted clinical, histological and microarray analyses on a mouse model of induced colitis. We used dextran sulfate sodium (DSS) to induce colitis in wild-type (WT) mice for 7 days. Simultaneously, mice were injected with either saline or one form of TSP-1 derived recombinant proteins, containing either (1) the three type 1 repeats of the TSP-1 (3TSR), (2) the second type 1 repeat (TSR2), or (3) TSR2 with the RFK sequence (TSR2+RFK). Total RNA isolated from the mice colons were processed and hybridized to mouse arrays. Array data were validated by real-time qPCR and immunohistochemistry. Histological and disease indices reveal that the mice treated with the TSRs show different patterns of leukocytic infiltration and that 3TSR treatment was the most effective in decreasing inflammation in DSS-induced colitis. Transcriptional profiling revealed differentially expressed (DE) genes, with the 3TSR-treated mice showing the least deviation from the WT-water controls. In conclusion, this study shows that 3TSR treatment is effective in attenuating the inflammatory response to DSS injury. In addition, the transcriptomics work unveils novel genetic data that suggest beneficial application of the TSR domains in inflammatory bowel disease.

Citation: Lopez-Dee ZP, Chittur SV, Patel B, Stanton R, Wakeley M, et al. (2012) Thrombospondin-1 Type 1 Repeats in a Model of Inflammatory Bowel Disease: Transcript Profile and Therapeutic Effects. PLoS ONE 7(4): e34590. doi:10.1371/journal.pone.0034590

Editor: Anthony W. I. Lo, The Chinese University of Hong Kong, Hong Kong

Received November 8, 2011; Accepted March 2, 2012; Published April 3, 2012

Copyright: © 2012 Lopez-Dee et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was supported by grants from the National Institutes of Health (DK067901-12 02), the Howard Hughes Medical Institute (grant # 52006328) and a Wilkes Mentoring grant. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: linda.gutierrez@wilkes.edu

† Current address: Department of Basic Sciences, The Commonwealth Medical College, Scranton, Pennsylvania, United States of America

Introduction

Thrombospondins (TSPs) are glycoproteins that are secreted into the extracellular matrix. They have important functions in development, inflammation, angiogenesis and cancer. The five members of this family (TSP-1 through 5) are all multimodular extracellular proteins. TSP-1 comprises a 450 kDa protein composed of three 150 kDa disulfide-linked polypeptide chains [1,2]. TSP-1 and TSP-2 organize into trimeric structures. Each subunit of the trimer consists of multiple domains: an N-terminal globular domain, a procollagen domain, three types of repeated sequence motifs (type 1, type 2, and type 3 repeats) and a C-terminal globular domain. TSP-1 and TSP-2 both have the thrombospondin type 1 repeat, also called thrombospondin structural repeats (TSRs). TSP-3, TSP-4 and TSP-5, on the other hand, lack the TSRs and procollagen domain; they also differ from TSP-1 and TSP-2 in their pentameric structure. The thrombospondins have been characterized in a variety of organisms, including Drosophila, other arthropods and vertebrates [3].

The TSRs are about 60 amino acids in length and are evolutionarily conserved [e.g., [2], [3–5]]. TSRs have roles in cell attachment and have been implicated in binding a variety of transmembrane and extracellular proteins. They have been shown also to have functions in the regulation of cell proliferation, migration and apoptosis in a variety of physiological and pathological events, such as wound healing, inflammation and inhibition of angiogenesis [6]. For example, by interacting with CD36 [7,8] and integrins [9], TSRs inhibit endothelial cell migration.

The various functions of the TSRs have been attributed to several recognition motifs. Characterization of these motifs has led to the use of recombinant proteins that contain these motifs; these recombinant proteins are deemed useful in cancer therapy [10,11]. The TSP-1 3TSR (that is, all three TSRs of the type 1 repeat domain) can activate transforming growth factor beta 1 (TGFβ1) and inhibit endothelial cell migration, angiogenesis, and tumor growth [10,12]. In an efficacy study of 3TSR on human pancreatic cancer cells, 3TSR reduced tumor volume by 69% and induced extensive necrosis after 3 weeks of treatment. 3TSR treatment also reduced tumor microvessel density and increased apoptosis in the endothelia of tumors [12].

The TGFβ1 activating sequence RFK is located between the first and second TSR. When a squamous cell carcinoma cell line
transfected with TSR2+RFK was injected into nude mice, TSR2+RFK inhibited in vivo tumor angiogenesis and growth in the mice. The tumors were shown to have increased levels of active TGFβ1. Treatment with TSR2 without RFK produced tumors that were slightly larger than the 3TSR and TSR2+RFK tumors [13]. However, mimetic peptides derived from TSR2, such as ABT-510 [14], decreased microvessel density and increased apoptosis in gliomas. ABT-510 was also effective in diminishing inflammation and angiogenesis in a murine model of inflammatory bowel disease (IBD) [15].

In this study, we evaluated the therapeutic effects of the subdomains of the TSP-1 TSRs using the DSS model of colitis and used a microarray approach to analyze the transcript profile of the mice treated with DSS and the TSRs. Our goals were to gain insight into the genes and pathways that are regulated upon TSR treatment and to determine the specific TSR treatment that would have the best potential for drug therapy. We were also interested in identifying novel genes not yet associated with and characterized in IBD, as well as putative intestinal stem cell genes. The results herein establish the efficacy of the 3TSR-containing recombinant protein in alleviating the inflammatory response to DSS injury as shown by improved clinical signs and lower perturbation of the transcriptome.

Materials and Methods

Mice

Wild-type (WT) mice (strain C57BL/6; n = 48) were purchased from Charles River Laboratories International (Wilmington, MA). Mice were bred at room temperature at the Wilkes University vivarium. All animal procedures were performed with the approval of the Wilkes University Institutional Animal Care and Use Committee and the U.S. National Institutes of Health (NIH) guidelines (Wilkes IACUC protocol # 189).

Dextran sulfate sodium (DSS) and TSR Treatments

DSS (MW: 36,000–50,000) (MP Biomedical, LLC, Aurora, OH) was dissolved in the drinking water (distilled) of the mice at a dilution of 2.5% (wt/vol) and administered to 6–7 week old mice for 7 days to induce acute colitis. Simultaneously, mice were subcutaneously injected daily with the following recombinant proteins: 3TSR (n = 10), TSR2 (n = 9) TSR2+RFK (n = 15). TSR doses were administered according to published results [10]. As a control for the TSR treatment, mice (n = 14) were injected with saline. Following 7 days of DSS administration, mice were sacrificed by CO2 asphyxiation.

Recombinant proteins were obtained from Dr. Jack Lawler (Harvard Medical School, Boston, MA). The 3TSR contains amino acids 361–530 of TSP-1; TSR2, amino acids 416–473; TSR2+RFK, amino acids 411–473 [10].

Clinical parameters and Disease Activity Indices

The clinical severity of the colitis was determined daily by disease activity indices according to a published protocol [15]. Stool consistency was evaluated as follows: formed feces = 1, soft consistency = 2 and liquid feces = 3. Presence of fecal occult blood was tested using the stool guaiac test; scoring was done as follows: 1 for negative by guaiac paper, 2 for positive only with guaiac paper, 3 for bloody feces.

Histology and inflammation grading in colonic tissues

Intestines were removed, opened longitudinally, and rinsed with ice-cold PBS. For morphologic studies, tissues were fixed in Histochoice MB fixative (Electron Microscopic Sciences, Hatfield, PA) overnight, processed and cut in serial 5-μm sections. Sections were stained with hematoxylin and eosin (H&E) for histopathological analysis. Inflammation was graded as follows: 0, no inflammation; 1, modest numbers of infiltrating leukocytes in the lamina propria; 2, infiltration of leukocytes leading to separation of crypts and mild mucosal hyperplasia; 3, massive infiltration of inflammatory cells accompanied by disrupted mucosal architecture and complete loss of goblet cells. Slides were double-coded before pictures were taken and frames blindly analyzed in a monitor.

RNA isolation

Colon segments (~1 cm long) were collected from treated and untreated mice and snap-frozen in liquid nitrogen. Total RNA was extracted from these tissues using the RNAqueous®-4PCR kit (Applied Biosystems), following the manufacturer’s instructions. RNA was DNase I-treated and quantified using the Nanodrop ND1000 spectrometer (Thermo Scientific, Wilmington, DE). RNA integrity was checked on a non-denaturing agarose gel. The microarray experiments are described in the following sections following the MIAME guidelines.

Microarray Processing

Total RNA from colons of at least three mice from each treatment group were submitted to the Center for Functional Genomics, University at Albany, Rensselaer, New York for microarray processing. Treatment groups included the mice treated with DSS and the TSR-containing recombinant proteins 3TSR, TSR2 and TSR2+RFK and mice treated with DSS+ saline injections as controls. Untreated WT were used as additional control. RNA integrity of the samples used for microarray hybridization was verified using Agilent’s 2100 Bioanalyzer (Santa Clara, CA). The Affymetrix (Santa Clara, CA) Mouse Gene 1.0 ST Array was used for the transcript profiling. 20 ng total RNA per sample was processed using WT Ovation Pico RNA Amplification System (NuGEN Technologies, Inc., San Carlos, CA). Sense target cDNAs were generated using the standard NuGEN WT protocol and hybridized to the arrays. Arrays were washed, stained on a FS 430 station and scanned on a GeneChip 3000 7G scanner using GeneChip® Command Console® Software (AGCC).

Statistical Analysis

Statistical analysis of the CEL files was done using GeneSpring GX 11.5.1 (Agilent Technologies). Signals were quantile-normalized using PLIER16 algorithm and baseline-transformed to the median of all samples. The log2 normalized signal values were filtered to remove entities that show signal in the bottom 20th percentile across all samples. This list was further filtered to only include entities where at least 1 out of 6 conditions have CV<30.0% (that is, to remove probes that are highly variable across replicates in a condition). The list was then subjected to ANOVA (p<0.05) that compares all conditions to the WT-water or WT-DSS saline condition. A Benjamini-Hochberg False Discovery Rate correction (p<0.05) was also included in the analysis. A 1.5-fold filter was applied to identify genes that are differentially expressed between any two specific conditions. Microarray data have been deposited in the Gene Expression Omnibus (GEO) database under accession number GSE32697.

Real-Time Quantitative PCR Validation of Array Data

Real-time quantitative PCR (RT-qPCR) was performed on colonic total RNA isolated from another set of three mice. To
obtain cDNAs, RNAs (2 μg) were reverse-transcribed using the High Capacity RNA-to-cDNA Kit (Applied Biosystems). This was followed by amplification of the unlabeled cDNAs with the Fast SYBR Green master mix (Applied Biosystems) and real-time quantification in the StepOne Plus Real-time PCR system. Amplification was performed with 40 cycles of 95°C for 3 sec, and 60°C for 30 sec, using 150 nM of each primer.

The use of Gapdh as endogenous control gene in the RT-qPCR validation was problematic with samples that were treated with the recombinant proteins. Preliminary qPCR runs showed fluctuating levels of Gapdh among the TSR-treated samples. Ubc, Gapdh, Rp523 and Tpt1 have been evaluated for suitability as internal control in colon cancer studies [16]. Using the GeneMANIA [17] prediction server (www.genemania.org), we found that Gapdh interacts with Igfhp5 (Figure S2). Our array data shows that Igfhp5 is up-regulated in WT-DSS mice. The Gapdh-Igfhp5 interaction suggests co-expression and could explain the high variability of Gapdh expression in our samples. On the other hand, query of Tpt1 in GeneMANIA showed that it is unrelated to any of our genes of interest.

For the RT-qPCR validation, we selected (1) representative genes from the major pathways that are activated as a response to inflammation, (2) genes that code for acute phase proteins, and (3) genes that have not been extensively characterized, especially in IBD. The genes validated are: calcypylosine-like (Cals), carboxyl reductase 3 (Cbcr3), CXC chemokine ligand 5 (Cxc5), epiregulin (Eng), haptoglobin (Hp), inhibin A (Inha), pentraxin related gene (Ptx3), insulin-like growth factor binding protein 5 (Igfbp5), matrix metalloproteinase 10 (Mmp10), also known as stromelysin-2, Mmp13, WAP four-disulfide core domain 12 (Wfcd12), serylgin (Sgpn), Sema (or cysteine) peptidase inhibitor, clade A, member 3N (Sempa3N), formyl peptide receptor (Fpr3) and leucine-rich repeat-containing G-protein coupled receptor (Lgr5). Expression levels of the 15 genes were normalized to the internal control, Tpt1 (tumor protein, translationally-controlled 1). The 2-ΔΔCt method was used to quantify the expression levels of the genes. Details on the reference and target genes are given in the Table S1.

Immunohistochemistry (IHC)
IHC sections were incubated overnight with the following antibodies: cluster of differentiation 31 (CD31) and Ly-6G/Ly-6C (RB6-8C5) (BD Pharmling, San Diego, CA), mouse panendothelial cell antigen (MECA-32) (BioLegend, San Diego, CA), Interleukin-6 (IL-6), cluster of differentiation 68 (Mac/CD68) and metalloproteinase 3 (MMP3) (Santa Cruz Biotechnologies Inc. Santa Cruz, CA), LGR5 and Calgranulin MRP8/S100A9 (Epitomics, Santa Cruz, CA), mouse panenolocyte antibodies: cluster of differentiation 31 (CD31) and Ly-6G/Ly-6C were scanned at low magnification and examined for areas with the highest number of leukocytic infiltration. The number of positive cells stained with Mac/CD68 or Ly-6G/Ly-6C was assessed at 400× magnification per field.

Results

Only 3TSR ameliorated clinical signs of colitis in the DSS-induced colitis

The presence of fecal blood was evaluated and rated in mice with DSS-induced colitis and treated with the TSRs (Figure 1A). While no significant differences were observed during the first 5 days of treatment, by days 6 and 7, 3TSR mice showed lesser fecal bleeding when compared with mice treated with saline, TSR2 and TSR2+RFK (day 6, 3TSR and saline p = 0.020; day 7, 3TSR and saline p = 0.045). Fecal consistency was also evaluated daily (Figure 1B). Again, by day 7, 3TSR mice displayed more solid feces compared to the liquid feces of saline-treated mice (p < 0.0001) and TSR2+RFK (p < 0.0001). TSR2 and TSR2+RFK mice showed more severe diarrhea than the controls (p < 0.0001). Inflammation and epithelial injury were significantly decreased in colons of the 3TSR mice when compared with the saline-treated mice (p = 0.001) (Figure 1C). Differences between 3TSR and the other two recombinant proteins were statistically significant (3TSR and TSR2+RFK: p = 0.034; 3TSR and TSR2: p = 0.025) (Figure 1D).

Angiogenesis was not inhibited by the TSRs

By using CD31/Meca stained slides, endothelial cells lining blood vessels were analyzed in colonic sections (Figure S1) from the treated mice. Vessel counts were not statistically different across the treatments (p = 0.074; 3TSR, n = 29, vessels = 21.48±2.1 and TSR2+RFK, n = 35, vessels = 21.4±1.5). However, colonic sections from TSR2 mouse showed a trend for lower counts (n = 20, vessels = 19.45±2.7) when compared to saline-treated colons (n = 16, vessels = 26.62±4.0) (Figure S1).

Colonic tissues from TSR-treated mice showed differential patterns of leukocytic infiltration

Sections stained with the antibody Ly-6G/Ly-6C were evaluated to identify granulocytes and monocytes (Figure 2A). Colonic sections from 3TSR- and TSR2-treated mice showed counts considerably lower than saline-treated colons, (with p = 0.030 and 0.047, respectively) (Figure 2B). Interestingly, counts obtained from the TSR2+RFK-treated colons were similar to the ones detected in saline-treated colons. The differences between TSR2 and TSR2+RFK were statistically significant (p = 0.021).

Macrophage infiltration was analyzed using Mac/CD68 antibody staining (Figure 2C). Though no differences were detected when each group was compared with the saline control, TSR2+RFK mice showed a significantly lower influx of macrophages compared with the controls and the TSR2 and 3TSR groups (p = 0.0006) (Figure 2D).

TSR treatment reduced the number of differentially expressed genes in the DSS induced colitis

Coincident treatment with 3TSR, TSR2+RFK and TSR2 show diminishing numbers of DE genes, with 3TSR showing the least number of DE genes (Figure 3A) when compared to either controls, WT-water or WT-DSS saline. The general trend of number of DE genes (when compared to WT-water) is as follows: WT-DSS-3TSR>WT-DSS-TSR2+RFK>WT-DSS-TSR2>WT-DSS-saline (Figure 3A). A heatmap of the top DE genes, eight up-regulated and four down-regulated, is shown in Figure 3B and the gene list is
A.

Average Fecal Blood Rating

Days

0 2 4 6 8

3 TSR  Saline  TSR2  TSR2 + RFK

B.

Average Fecal Consistency Rating

Days

0 2 4 6 8

3 TSR  Saline  TSR2  TSR2 + RFK

C.

3TSR  Saline

TSR2  TSR2 + RFK

D.

Inflammation grade

0 0.5 1.0 1.5 2.0 2.5 3.0

3TSR  Saline  TSR2  TSR2 + RFK

*
presented in Table 1. Focusing on the 3TSR, only 43 genes were up-regulated and two genes were down-regulated in the 3TSR vs WT-DSS saline comparison. Figure 3C presents a heatmap of the top 14 DE genes in this pair. The numbers of up- and down-regulated genes in the 3TSR treatment group diminished when compared to either TSR2 or TSR2+RFK (Figures 3D and 3E). Table 2 presents the top 12 genes that are up-regulated in the 3TSR-treated group and the two down-regulated genes, using the WT-DSS-saline as reference. Although some genes involved in the inflammatory response were up-regulated in 3TSR, their level of up-regulation was much lower than in the other TSR treatment groups. The complete list of differentially expressed genes (FC > 1.5; p < 0.1) is provided in the Table S2.

**DSS and the TSR treatments up-regulated key genes involved in inflammation, cell adhesion and apoptosis**

Genes up-regulated in the DSS and TSR-treatment groups belong to the following pathways: (1) matrix metalloproteinases, (2) inflammatory response, (3) peptide GPCRs, (4) eicosanoid/prostaglandin synthesis regulation, (5) TGF-beta signaling, (6) matrix metalloproteinases.

---

**Figure 1. Fecal blood and consistency rating in mice treated with DSS and TSRs over one week.** While no significant differences were observed during the first days of treatment, by days 6 and 7, mice treated with the 3TSR (n = 10) showed lesser fecal bleeding when compared with mice treated with the saline (n = 14), TSR2 (n = 9) and TSR2+RFK (n = 15), (day 6: p = 0.02; day 7: p = 0.045, asterisk) (A). Fecal consistency was also evaluated daily (B). By day 7, 3TSR mice displayed more solid feces compared to the liquid feces of saline-treated mice (p < 0.0001, asterisk) and TSR2+RFK (p < 0.0001). Inflammation grading (C, D) was assessed and H&E stained sections. Decreased inflammation was observed in sections of colons from 3TSR-treated mice (n = 9) compared to colons from mice treated with TSR2+RFK (n = 12), TSR2 (n = 10) and saline (n = 7). 400× original magnification. doi:10.1371/journal.pone.0034590.g001

**Figure 2. Immunohistochemistry (IHC) with the Ly-6G/Ly-6C antibody for detection of granulocytes and monocytes in colitic sections.** Counts of Ly-6G/Ly-6C positive cells in TSR2 and 3TSR were considerably lower than in saline (n = 5 in each group) and TSR2+RFK-treated (n = 9) colons (A). However, only TSR2 showed lower counts that were statistically significant, p = 0.047 (B). IHC against Mac/CD68 (C) showed fewer CD68 positive cells (macrophages) in TSR2+RFK (n = 24) compared to TSR2 (n = 14) and saline (n = 18). These differences were statistically significant, p = 0.0006, when compared with 3TSR-treated (n = 18) colons (D). 400× magnification. doi:10.1371/journal.pone.0034590.g002
smooth muscle contraction, (7) integrin-mediated cell adhesion and (8) apoptosis (Table 3). S100 calcium binding protein A9 (S100a9; also known as calgranulin B) had the highest transcript level in all treatment groups, with the WT-DSS group showing the highest FC (81), whereas the WT-DSS-3TSR has FC = 18 (Table S2). An inflammatory response was indicated by the high transcript levels of \( \text{Il-6} \) [WT-DSS-TSR2 (FC = 18) + RFK (FC = 7)]. WT-DSS-TSR2 (FC = 18) + RFK and WT-DSS-3TSR (FC = 4). Chemokines, specifically Cxcl2, Cxcl5, Cxcl13, Cxcl16, Ccl3 and Ccl7, were also up-regulated (FC = 2 to 60) in the treated samples. Cxcl2, in particular, had the greatest increase in the WT-DSS-TSR2 (FC = 55) compared to the other TSR-treated mice. Genes involved in inflammation and angiogenesis including Adamts9, Tnf alpha and the TNF receptor Tnfrsf1b, were enriched the most in the WT-DSS and WT-DSS-TSR2 groups.

Genes coding for proteins that are well known to interact with TSP-1 during inflammation were differentially expressed in DSS and TSR-treated mice, except in the 3TSR group. Cd47 was only slightly up-regulated in WT-DSS-TSR2 (1.8). It was not DE in TSR2+RFK and 3TSR. Tgfβ1 was also slightly up-regulated in TSR2 (FC = 2.5) and TSR2+RFK (FC = 1.8), but not in 3TSR. None of the treatment samples showed differential expression of Cldn6.

Real-time qPCR validation

Actual qPCR data revealed no fluctuation in expression of the internal control gene, Tpt1, which was consistent with the microarray data. We validated 15 DE genes to verify the array data. Figure 4 summarizes the validation for representative genes coding for acute phase proteins, growth factors and novel proteins. Validation for the metalloproteinases and genes coding for cytokines and a protein important for intestinal homeostasis are shown in Figure S3. Although Sign and Wfel12 have p-values greater than 0.05, (Sign p = 0.056, Wfel12 p = 0.065), the real-time qPCR validation shows that they are indeed differentially expressed.
| Gene Name                                      | Gene symbol | Refseq       | Corrected p-value | Fold change (vs [WT-water]) | Gene Ontology                                                                 |
|-----------------------------------------------|-------------|--------------|-------------------|----------------------------|--------------------------------------------------------------------------------|
| **Up-regulated genes**                       |             |              |                   | [WT-DSS saline] | [WT-DSS-3TSR] | [WT-DSS-TSR2] | [WT-DSS-TSR2+RFK] |
| S100 calcium binding protein A9 (calgranulin B) | S100a9      | NM_009114    | 0.026             | 10.34 | 18.94 | 74.93 | 43.08 | leukocyte chemotaxis/actin cytoskeleton reorganization/regulation of integrin biosynthetic process/calcium binding |
| S100 calcium binding protein A8 (calgranulin A) | S100a8      | NM_013650    | 0.031             | 4.57  | 9.39  | 54.98 | 31.60 | chemotaxis/calcium ion binding |
| Chemokine (C-X-C motif) ligand 2              | Cxcl2       | NM_009140    | 0.029             | 4.96  | 14.01 | 55.19 | 31.89 | chemotaxis/inflammatory response/immune response/signal transduction/cytokine/chemokine activity/extracellular region/space |
| Matrix metallopeptidase 3                    | Mmp3        | NM_010809    | 0.048             | 4.95  | 10.10 | 69.20 | 21.49 | proteolysis/collagen catabolic process/catalytic/metalloendopeptidase/stromelysin 1 activity/calcium/Zn ion binding/hydrolase activity/proteinaceous extracellular matrix |
| Matrix metallopeptidase 10                   | Mmp10       | NM_019471    | 0.036             | 4.54  | 17.11 | 74.14 | 29.54 | proteolysis/metabolic/collagen catabolic process/catalytic/metalloendopeptidase activity/calcium/Zn binding/hydrolase/stromelysin 2 activity/proteinaceous extracellular matrix |
| Interleukin 1 beta                           | Il1b        | NM_008361    | 0.030             | 3.07  | 9.59  | 39.65 | 15.96 | fever/inflammatory/immune response/cell proliferation/neutrophil chemotaxis/positive regulation of kappaB kinase/NF-kappaB cascade/positive regulation of chemokine (IL-6) biosynthetic process/positive regulation of JNK cascade/leukocyte migration/PL-1 receptor binding/cytokine, growth factor activity/extracellular region/space |
| Chemokine (C-X-C motif) ligand 5              | Cxcl5       | NM_009141    | 0.030             | 1.30  | 3.33  | 24.56 | 5.37  | chemotaxis/inflammatory response/signal transduction/cytokine/chemokine activity/extracellular region/space |
| Serine (or cysteine) peptidase inhibitor clade A, member 3N | Serpina3n | NM_009252    | 0.030             | 4.92  | 4.22  | 17.01 | 8.73  | acute-phase response/serine-type endopeptidase inhibitor activity/extracellular region/space |
| **Down-regulated genes**                     |             |              |                   |               |               |               |               |                   |
| Carbonyl reductase 3                         | Cbr3        | NM_173047    | 0.044             | −1.54 | −2.22 | −4.64 | −2.31 | metabolic process/carbonyl reductase (NADPH) activity/oxidoreductase activity/cytosol |
| Abhydrolase domain containing 3              | Abhd3       | NM_134130    | 0.046             | −1.62 | −2.13 | −4.42 | −2.43 | no biological data available/Carboxylesterase activity/hydrolase activity/integral to membrane |
| RIKEN cDNA 061001F06 gene                    | 061001F06Rk | NM_026686    | 0.047             | −1.55 | −1.44 | −2.63 | −1.81 | −//methyltransferase activity/transferase activity |
| Calcyphosine-like                            | Capsl       | NM_029341    | 0.028             | −2.41 | −2.26 | −3.20 | −2.93 | −//calcium ion binding/cytoplasm |

doi:10.1371/journal.pone.0034590.t001
Table 2. Top 14 differentially-expressed genes in the 3TSR group.

| Gene name                        | Gene symbol | Refseq   | Corrected p-value | Fold change (vs WT-DSS saline) | Pathway or (Gene Ontology)* |
|----------------------------------|-------------|----------|------------------|-------------------------------|-----------------------------|
| **Up-regulated**                 |             |          |                  |                               |                             |
| Interleukin 1 alpha              | Il1a        | NM_010554| 0.036            | 3.84                          | 6.97                        | 15.18                       | −1.41 | Inflammatory_Response_Pathway |
| Matrix metallopeptidase 10       | Mmp10       | NM_019471| 0.036            | 3.77                          | 6.51                        | 16.33                       | −4.54 | Matrix_Metalloproteinases     |
| Inhibin beta-A                   | Inhba       | NM_008380| 0.038            | 3.45                          | 5.57                        | 13.86                       | −1.40 | TGF_Beta_Signaling_Pathway   |
| Prostaglandin-endoperoxide synthase 2 | Ptg2       | NM_011198| 0.034            | 3.16                          | 4.90                        | 10.37                       | −1.59 | Eicosanoid_Synthesis///Prostaglandin_synthesis_regulation |
| Interleukin 1 beta               | Il1b        | NM_008361| 0.030            | 3.13                          | 5.21                        | 12.94                       | −3.07 | Inflammatory_Response_Pathway///Smooth_muscle_contraction |
| Chemokine (C-X-C motif) ligand 2 | Cxcl2       | NM_009140| 0.029            | 2.82                          | 6.43                        | 11.12                       | −4.96 | (inflammatory response/immune response/neutrophil chemotaxis///extracellular) |
| Epieregulin                      | Ereg        | NM_007950| 0.039            | 2.68                          | 3.84                        | 8.80                        | −1.98 | (angiogenesis//positive regulation of cytokine production//epidermal growth factor receptor signaling pathway) |
| Chemokine (C-X-C motif) ligand 5 | Cxcl5       | NM_009141| 0.030            | 2.56                          | 4.14                        | 18.92                       | −1.30 | (cytokine production///chemotaxis///inflammatory response///immune response) |
| Non-SMC condensin I complex, subunit G | Ncapg | NM_019438| 0.045            | 2.56                          | 1.40                        | 1.75                        | 3.21  | (no biological data available) |
| Chemokine (C-X-C motif) receptor 2 | Cxcr2     | NM_009909| 0.040            | 2.55                          | 6.18                        | 16.62                       | −1.94 | (apoptosis///chemotaxis///signal transduction///G-protein coupled receptor protein signaling pathway) |
| Early growth response 2         | Egr2        | NM_010118| 0.038            | 2.45                          | 2.49                        | 5.05                        | −1.34 | (regulation of ossification///response to insulin stimulus///positive regulation of transcription from RNA polymerase II promoter) |
| C-type lectin domain family 4, member e | Clec4e | NM_019948| 0.044            | 2.42                          | 5.24                        | 10.30                       | −1.51 | (integral to membrane///sugar binding) |
| **Down-regulated**              |             |          |                  |                               |                             |
| N-acetylated alpha-linked acidic dipeptidase-like 1 | Naald1    | NM_001009546| 0.045          | −1.55                        | −1.59                       | −1.84                       | 1.26  | (proteolysis///metalloproteinase activity///integral to membrane) |
| Zinc finger and BTB domain containing 16 | Zbtb16 | NM_001033324| 0.038          | −1.95                        | −1.22                       | −1.55                       | −2.13 | (hemopoiesis///transcriptional repressor complex///protein C-terminus binding) |

*The gene ontology is given, enclosed in brackets, where pathway has not been annotated in the microarray datasheet.
doi:10.1371/journal.pone.0034590.t002
IHC validation of genes recognized in stem cell biology, cancer and inflammation

Array data show that Lgr5, an intestinal stem cell biomarker [18,19], was down-regulated in the TSR2-treated WT mice. Lgr5 was not differentially expressed in the 3TSR and TSR2+RFK mice. However, results obtained in the RT-qPCR validation show that Lgr5 was significantly down-regulated in the TSR2+RFK (Figure 4B).

MMP3, IL-6 and Calgranulin (MRP8) are relevant in angiogenesis and inflammation. Validation by IHC of these genes (Figure 5) showed the MMP3 protein localized in the cytoplasm of epithelial cells and endothelial cells. Strong positive staining for MMP3 was detected mainly in monocytes, polymorphonuclears, plasma and fibroblasts. Stromal staining was detected in the submucosa. Endothelial cells and the leukocytic infiltrate in inflamed areas were positive for IL-6. MRP8 staining was observed almost exclusively in polymorphonuclears.

Discussion

Our results indicate that 3TSR suppressed the inflammatory response induced by DSS injury and these data are supported by the array results. For pharmacological consideration, it is logical to assume that the lesser the perturbation of the transcriptome, the better the clinical outcome. Our results also confirm the finding that TSR2 is less effective than either 3TSR or TSR2+RFK [10]. 3TSR has been shown to induce endothelial cell apoptosis and inhibit tumor growth [11]. This function may be correlated to the modulation of VEGFR2 function by TSP-1 and 3TSR [20].

One of the unexpected findings when clinical parameters were evaluated was the severity of the bleeding and diarrhea in mice treated with TSR2 and TSR2+RFK. These results do not agree with previous studies using the ABT-510, a TSR2 mimetic peptide [15]. In the ABT-510 studies, osmotic mini-pumps were used for the continuous delivery of the peptide in contrast to the daily injections used in this study. Moreover, increased eNOS activity has been attributed to increased mucosal blood flow in induced colitis [21] and TSP-1 is known to regulate nitric oxide (NO) signaling [22]. Noteworthy is the lesser influx of granulocytes in the TSR2 mice compared to the TSR2+RFK and the 3TSR. This suggests that the TSR2 domain inhibits the influx of granulocytes independently of the RFK domain. TSR2 has been demonstrated to inhibit the secretion of NO during the acute phase of inflammation, and therefore decreasing the trafficking of neutrophils [23]. On the other hand, RFK presumably inhibits inflammation by activating TGFß1. However, recent studies suggest that when there is a high secretion of IL-1 and IL-6, TGFß1 will favor the production of Th17 cells. Th17 cells secrete pro-inflammatory cytokines and metalloproteinases that exacerbate the inflammatory response [23].

Our array data showed that metalloproteases and chemokines such as MMP10, MMP13, the CCs and CXCs are involved in the pathogenesis of DSS colitis. Expression of Cxcl2 and Cxcl5 (Figure S3B), the proteins of which are known to target neutrophils and have suspected roles in IBD, was significantly increased in the DSS and TSR-treated mice during the acute phase of colitis. The increase in Cxcl2 expression is the same observation reported for the leptin receptor-deficient mice that were treated with DSS [24]. An irregularity in chemokine signaling could jeopardize epithelial integrity, which could lead to the breakdown of defense against invading pathogens. Moreover, Cxcl5 has a great potential in eliciting a pro-angiogenic phenotype [25].

The concentration of acute phase proteins is known to increase or decrease during inflammation. Hp and Ptx3, both of which are enriched in the DSS and TSR-treated mice, code for acute phase proteins. In a study of Hungarian patients with Crohn’s disease (CD), Hp polymorphism was determined to be associated with CD and inflammatory disease behavior [26]. Hp has been suggested to have a protective role in inflammatory colitis [27]. Ptx3 has been annotated to “positive regulation of nitric oxide biosynthetic process” and to “zymosan binding”.

This study showed strong evidence for the alteration of gene expression in DSS-induced colitis that supports vulnerability to cancer. As an example, calgranulins, S100A8/A9 (calgranulins A and B, respectively), have been detected in various human cancers; hence they have been suggested to play a key role in inflammation-associated cancer [28]. They support epithelial barrier function and mediate responses to infection and inflammation [29] by amplifying pro-inflammatory responses [30]. In gastrointestinal epithelial cells, their expression is induced during inflammation and increased protein expression of S100A9 has been detected in colitis-related carcinogenesis in mice [31]. Key genes associated with colon tumor progression are reportedly activated by S100A8/A9 [32].

The ‘novel’ genes that we validated appear to have a role, one way or another, in inflammatory response and the promotion of inflammation-related cancer development. The function of these

### Table 3. Major pathways activated and genes enriched in the DSS- and TSR-treated mice.

| Pathways                                      | Genes up-regulated (fold change>2.0, p<0.05)                                                                                   |
|-----------------------------------------------|-------------------------------------------------------------------------------------------------------------------|
| Matrix metalloproteinases                      | Matrix metalloproteinases 2, 3, 8, 10, 12, 13, 14                                                                      |
| Inflammatory response                         | Interleukin 1 alpha (Il1a), IL10, IL-6, Interleukin 4 receptor, alpha (Ihr4a), IL12                                  |
| Peptide GPCRs                                 | Formyl peptide receptor 3 (Fpr3)                                                                                       |
| Eicosanoid/prostaglandin synthesis regulation | Prostaglandin-endoperoxide synthase 2 (Ptg2)                                                                          |
| TGF-beta signaling                            | Inhibin beta-A (inhba)                                                                                                |
| Smooth muscle contraction                     | Insulin-like growth factor binding protein 5 (Igfbp5)                                                                  |
| Blood clotting cascade/Wnt signaling          | Plasminogen activator, urokinase (Plau)                                                                               |
| Integron-mediated cell adhesion                | Integrins alpha M (Itgam), beta 2 (Itgb2), Itgα4                                                                      |
| Apoptosis                                      | B-cell leukemia/lymphoma 2 related protein A1a (Bcl2a1a), Bcl2a1b, Bcl2a1c, Bcl2a1d; Tumor necrosis factor (Tnf), TNF receptor superfamily, member 1a (Tnfrsf1a), Tnfrsf1b |
| Ovarian infertility Genes                     | Early growth response 2 (Egr2), CCAAT/enhancer binding protein (C/EBP), beta (Cebpβ)                                  |

doi:10.1371/journal.pone.0034590.t003
genes as they relate to diseases and how these genes interact with other genes have not been extensively studied. The description ascribed to them in the gene ontology database, however, indicates some involvement in the development of physiological disorders.

Genome-wide association studies have identified \textit{Capsl} to have association with type 1 diabetes [33] and the autoimmune thyroid disease Graves’ disease [34]. \textit{Cbr3}, an enzyme that reduces carbonyl groups in xenobiotics and endogenous compounds such as...
as steroids and eicosanoids, has been suggested to have a minor role in xenobiotic metabolism in humans [35]. Ereg is a growth factor that resides in the extracellular space and is a marker for ovarian cancer development [36]. Fpr3 is a member of a G-protein coupled receptor family that controls immune responses such as leukocyte chemotaxis and activation [37]. Serpina3n has been found to inhibit human Granzyme B activity in sertoli cells as a mechanism to suppress the immune response [38]. SRGN is a proteoglycan that has important roles in inflammatory reactions [39]. In human endothelial cells, it co-localizes and interacts with tissue-type plasminogen activator (PLAT) [40]. In macrophages, where it is the major secreted proteoglycan, it regulates the secretion of TNF [41]. The up-regulation of Srgn (Figure S3B) in the DSS- and TSR-treated mice suggests that it is a component of the immune response in these mice.

SRGN is a proteoglycan that has important roles in inflammatory reactions [39]. In human endothelial cells, it co-localizes and interacts with tissue-type plasminogen activator (PLAT) [40]. In macrophages, where it is the major secreted proteoglycan, it regulates the secretion of TNF [41]. The up-regulation of Srgn (Figure S3B) in the DSS- and TSR-treated mice suggests that it is a component of the immune response in these mice.

The significance of Wfcl2 up-regulation in the DSS- and TSR-treated mice (Figure S3C), lies in the fact that an altered microbiota composition in the intestinal tract characterizes the pathogenesis of IBD [42,43]. WFDCC12 is an antibacterial protein that inhibits the growth of both E. coli and S. aureus at a IC90 of 10 μM [44]. With its anti-infective activity, it could serve as mucosal defense against pathogenic bacterial strains, in conjunction with chemokine signaling.

Evidence for involvement of Insulin-like growth factor (IGF) signaling in cancer progression has been increasing [45]. IGF signaling plays a critical role in promoting cell survival and proliferation of embryonic and adult stem cells [46]. IGFBP5 is associated with “stemness” and its expression has been linked to LGR5, which has been shown to be expressed in cycling columnar epithelial cells at the intestinal crypt base [18,19]. LGR5-deficient mice showed decreased Lgfbp5 expression [47]. Erosive lesions in the intestinal epithelium due to DSS could account for the lower transcript levels of Lgr5 in the DSS-treated mice. LGR5 deficiency was reported to deregulate the Wnt pathway and contribute to cancer [47].

In conclusion, this study showed that the 3TSR have anti-inflammatory properties that seem to be independent of any angiogenic inhibition or ability to activate TGFß1. These data highlight the anti-inflammatory functions of the 3TSR of TSP-1 in the mouse intestine and its potential use as novel therapeutic tool in IBD. The transcript profiles of the treatment groups showed a pool of genes involved in critical pathways of inflammation. The identification of these genes has implications in improving our
understanding of the pathophysiology of IBD. Further characterization of their protein products and their interactions could provide leads in the development of other drug therapy for IBD.

Supporting Information

Figure S1 Assessment of microvessel counts. Using combined MECA/CD31 antibodies (A), fewer blood vessels were observed in sections from TSR2 mice (n = 20) compared to sections from mice treated with TSR2+RFK (n = 35), 3TSR (n = 29) or saline (n = 16), (B). 400 x magnification. (TIF)

Figure S2 A functional association network of selected mouse genes. GeneMANIA, a web interface for predicting gene function and determining usability of genes for functional assays (www.genemania.org) was used to determine suitability of endogenous control genes for validating array data by RT-qPCR. The following genes (grey circles) were inputted in GeneMANIA: Ubc, Tpt1; Rps27; Gapdh; Caps3; Igf5p; Fpr3; Sgce; kcnj10; Mmp10; Mmp13; Wdk12. The network generated shows interaction between Gapdh and Igf5p; therefore, Gapdh expression is likely to be co-expressed with Igf5p and show varying expression levels similar to that of Igf5p. Tpt1, on the other hand, has no predicted interaction with any of the input genes. (TIF)

Figure S3 Additional RT-qPCR validation of array data. (TIF)

Table S1 Genes used for the RT-qPCR validation and their primers. Tpt1 was used as the control gene after it was found to show no fluctuation compared to four other genes that were tested. (XLSX)

Table S2 ANOVA list of genes that were differentially expressed in the colons of DSS and TSR-treated mice. (XLS)

Acknowledgments

We thank Dr. Jack Lawler (Beth Israel Deaconess Medical Center, Boston, MA) for providing the TSR recombinant proteins. We also thank Dr. Willbur Hayes (Emeritus, Wilkes University) for his relevant comments on the manuscript.

Author Contributions

Conceived and designed the experiments: LG ZLD BV MW BL AM BE RT SVC. Performed the experiments: LG ZLD BS BL AM BE RT SVC. Contributed reagents/materials/analysis tools: LG SVC. Wrote the paper: ZLD LG SVC.

References

1. Lawler J (1986) The structural and functional properties of thrombospondin. Blood 67: 1197–1209.
2. Lawler J, Hynes RO (1986) The structure of human thrombospondin, an adhesive glycoprotein with multiple calcium-binding sites and homologies with several different proteins. J Cell Biol 103: 1635–1646.
3. Carlson CB, Lawler J, Mosher DF (2008) Structures of thrombospondins. Cell Mol Life Sci 65: 672–686.
4. Adams JC, Tucker RP (2000) The thrombospondin type 1 repeat (TSR) superfamily: diverse proteins with related roles in neuronal development. Dev Dyn 218: 280–299.
5. Tucker RP (2004) The thrombospondin type 1 repeat superfamily. Int J Biochem Cell Biol 36: 969–974.
6. Chen H, Herndon ME, Lawler J (2000) The cell biology of thrombospondin-1. Matrix Biol 19: 597–614.
7. Simantov R, Silverstein RL (2003) CD36: a critical anti-angiogenic receptor. Front Biosci 8: 4714–4722.
8. Simantov R, Febraro M, Silverstein RL (2005) The antiangiogenic effect of thrombospondin-1 is mediated by CD69 and modulated by histidine-rich glycoprotein. Matrix Biol 24: 27–34.
9. Short SM, Derrien A, Narasimhan RP, Lawler J, Ingber DE, et al. (2005) Inhibition of endothelial cell migration by thrombospondin-1 type-1 repeats is mediated by beta1 integrins. J Cell Biol 168: 643–653.
10. Miao WM, Seng WL, Duquette M, Lawler J, Laua C, et al. (2001) Thrombospondin-1 type 1 repeat recombinant proteins inhibit tumor growth through Transforming growth factor-B-dependent and -independent mechanisms. Cancer Res 61: 7300–7309.
11. Ren B, Song K, Parangi S, Jin T, Ye M, et al. (2009) A double hit to kill tumor and endothelial cells by TRAIL and antiangiogenic 3TSR. Cancer Res 69: 3856–3865.
12. Zhang X, Galardi E, Duquette M, Delic M, Lawler J, et al. (2005) Antiangiogenic treatment with the three thrombospondin-1 type 1 repeats recombinant protein in an orthotopic human pancreatic cancer model. Clin Cancer Res 11: 2327–2344.
13. Vee KO, Streit M, Hawighorst T, Demar M, Lawler J (2004) Expression of the type-1 repeats of thrombospondin-1 inhibits tumor growth through activation of transforming growth factor-beta. Am J Pathol 165: 541–552.
14. Havel F, Bradley MF, Kahin DM, Schneider AJ, Davidson DJ, et al. (2005) Thrombospondin-1 mimetic peptide inhibitors of angiogenesis and tumor growth: design, synthesis, and optimization of pharmacokinetics and biological activities. J Med Chem 48: 2383–2386.
15. Panekar S, Zal S, Kohler VG, Dobranyi L, Panekar I, et al. (2008) Thrombospondin 1 and its mimetic peptide ABT-510 decrease angiongenesis and inflammation in a murine model of inflammatory bowel disease. Pathobiology 75: 9–21.
16. Anderson CL, Jensen JL, Ornoth TF (2004) Normalization of real-time quantitative reverse transcription-PCR data: a model-based variance estimation approach to identify genes suited for normalization, applied to bladder and colon cancer data sets. Cancer Res 64: 5245–5250.
17. Warle-Farley D, Donaldson SL, Comes O, Zuberi K, Badravi R, et al. (2010) The GeneMANIA prediction server: biological network integration for gene prioritization and predicting gene function. Nucleic Acids Res 38: W214–220.
18. Barker N, van Es JH, Kuipers J, Kujala P, van den Born M, et al. (2007) Identification of stem cells in small intestine and colon by marker gene Lgr5. Nature 449: 1003–1007.
19. Sato T, van Es JH, Snippert HJ, Stange DE, Vries RG, et al. (2011) Paneth cells constitute the niche for Lgr5 stem cells in intestinal crypts. Nature 469: 415–418.
20. Zhang X, Kazerosarian S, Duquette M, Peruzzi C, Nagy JA, et al. (2009) Thrombospondin-1 modulates vascular endothelial growth factor activity at the receptor level. FASEB J 23: 3368–3376.
21. Peterson J, Schreiber O, Stege A, Patakz A, Hellenst A, et al. (2007) cNOS involved in colitis-induced mucosal blood flow increase. Am J Physiol Gastrointest Liver Physiol 293: G1291–1297.
22. Isenberg JS, Martin-Manoso M, Maxhimer JB, Roberts DD (2009) Regulation of nitric oxide signalling by thrombospondin 1: implications for anti-angiogenic therapies. Nat Rev Cancer 9: 182–194.
23. Foggia LA (2010) Role of transforming growth factor-beta in inflammatory bowel disease and colitis-associated colon cancer. Inflamm Bowel Dis 16: 1963–1968.
24. Gove ME, Rhodes DH, Piri M, van Baal JW, Sennello JA, et al. (2009) Role of lepton receptor-induced STAT5 signaling in modulation of intestinal and hepatic inflammation in mice. J Leukoc Biol 85: 491–496.
25. Mollodohvica A, Berek A, Eldridge L, Wagner EM (2010) Differential activity of pro-angiogenic CXC chemokines. Microvasc Res 80: 18–22.
26. Papp M, Lakkatos PL, Hungarian IBDG, Palatka K, Foldi I, et al. (2007) Haptoglobin polymorphisms are associated with Crohn's disease, disease behavior, and extraintestinal manifestations in Hungarian patients. Dig Dis Sci 52: 1297–1304.
27. Marquez L, Shen C, Cleven I, De Hertogh G, Van Steen K, et al. (2011) Effects of haptoglobin polymorphisms and deficiency on susceptibility to inflammatory bowel disease and on severity of murine colitis. Gut.
28. Gebhardt C, Nemeth J, Angel P, Hess J (2006) S100A8 and S100A9 in activated protein kinase in rheumatoid arthritis. Arthritis Res Ther 8: R69.
29. Fernandez-Granda M, Batista CS, Garcia A, Maes J, Baeza M, et al. (2010) Anti-inflammatory properties of s100 calcgranulins. Antiinflamm Antiallergy Agents Med Chem 8: 290–305.
30. Sunahori K, Yamamura M, Yamana J, Takasugi K, Kawashima M, et al. (2006) A double hit to kill tumor and endothelial cells by TRAIL and antiangiogenic 3TSR. Cancer Res 69: 3856–3865.
33. Santiago JL, Alizadeh BZ, Martínez A, Espino L, de la Calle H, et al. (2008) Study of the association between the CAPSL-IL7R locus and type 1 diabetes. Diabetologia 51: 1653–1658.
34. Todd JA, Walker NM, Cooper JD, Smyth DJ, Downes K, et al. (2007) Robust associations of four new chromosome regions from genome-wide analyses of type 1 diabetes. Nat Genet 39: 857–864.
35. Pilka ES, Niesen FH, Lee WH, El-Hawari Y, Dunford JE, et al. (2009) Structural basis for substrate specificity in human monomeric carbonyl reductases. PLoS One 4: e7113.
36. Amsterdam A, Sheeen E, Raanan C, Sillat Y, Ben-Arie A, et al. (2011) Epiregulin as a marker for the initial steps of ovarian cancer development. Int J Oncol 39: 1163–1172.
37. Migeotte I, Communi D, Parmentier M (2006) Formyl peptide receptors: a promiscuous subfamily of G protein-coupled receptors controlling immune responses. Cytokine Growth Factor Rev 17: 501–519.
38. Sprouse S, Summen KC, Lord SJ, Motyka B, Ewen C, et al. (2006) Identification of a novel human granzyme B inhibitor secreted by cultured sertoli cells. J Immunol 177: 5051–5058.
39. Kolset SO, Tveit H (2008) Serglycin: structure and biology. Cell Mol Life Sci 65: 1073–1085.
40. Schick BP, Gradowski JF, San Antonio JD (2001) Synthesis, secretion, and subcellular localization of serglycin proteoglycan in human endothelial cells. Blood 97: 449–458.
41. Zernichow L, Ahsan M, Hallgren J, Gruijc M, Pejler G, et al. (2006) Serglycin is the major secreted proteoglycan in macrophages and has a role in the regulation of macrophage tumor necrosis factor-alpha secretion in response to lipopolysaccharide. J Biol Chem 281: 26792–26801.
42. Ott SJ, Musfeldt M, Wendroth DF, Hampe J, Brant O, et al. (2004) Reduction in diversity of the colonic mucosa associated bacterial microflora in patients with active inflammatory bowel disease. Gut 53: 685–693.
43. Swidsinski A, Loening-Baucke V, Herber A (2009) Mucosal flora in Crohn’s disease and ulcerative colitis - an overview. J Physiol Pharmacol 60 Suppl 6: 61–71.
44. Hagiwara K, Kakuchi T, Endo Y, Hugun, Usui K, et al. (2005) Mouse SWAM1 and SWAM2 are antibacterial proteins composed of a single whey acidic protein motif. J Immunol 175: 1973–1979.
45. Samani AA, Yakar S, LeRoith D, Brodh P (2007) The Role of the IGF System in Cancer Growth and Metastasis: Overview and Recent Insights. Endocrine Reviews 28: 20–47.
46. Li Y, Geng YJ (2010) A potential role for insulin-like growth factor signaling in induction of pluripotent stem cell formation. Growth Horm IGF Res 20: 391–396.
47. Garcia MI, Ghianni M, Lefort A, Libert F, Strollo S, et al. (2009) LGR5 deficiency deregulates Wnt signaling and leads to precocious Paneth cell differentiation in the fetal intestine. Dev Biol 331: 58–67.